Carregant...
Combination of vaccine and immune checkpoint inhibitor is safe with encouraging clinical activity
This commentary provides the authors’ perspective on the article “Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial,” which has recently been published in The Lancet Oncology.
Guardat en:
| Autors principals: | , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Landes Bioscience
2012
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3494633/ https://ncbi.nlm.nih.gov/pubmed/23170267 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/onci.20591 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|